

(51) International Patent Classification ⁴ : A61K 39/395, C12N 15/00 C12P 21/00	A2	(11) International Publication Number: WO 89/ 01783
		(43) International Publication Date: 9 March 1989 (09.03.89)

<p>(21) International Application Number: PCT/GB88/00731</p> <p>(22) International Filing Date: 5 September 1988 (05.09.88)</p> <p>(31) Priority Application Number: 8720833</p> <p>(32) Priority Date: 4 September 1987 (04.09.87)</p> <p>(33) Priority Country: GB</p> <p>(71) Applicant (for all designated States except US): CELL-TECH LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only) : BODMER, Mark, William [GB/GB]; 131 Reading Road, Henley-on-Thames, Oxfordshire RG19 1DJ (GB). ADAIR, John, Robert [GB/GB]; 23 George Road, Stokenchurch, High Wycombe HP14 3RN (GB). WHITTLE, Nigel, Richard [GB/GB]; 5 Leigh Road, Cobham, Surrey KT11 2LF (GB).</p>	<p>(74) Agent: MERCER, Christopher, Paul; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, RO, SE (European patent), SU, US.</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
--	--

(54) Title: RECOMBINANT ANTIBODY AND METHOD

(57) Abstract

The present invention provides a humanised antibody molecule (HAM) having specificity for the TAG-72 antigen and having an antigen binding site wherein at least the complementarity determining regions (CDRs) of the variable domain are derived from the mouse monoclonal antibody B72.3 (B72.3 MAAb) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin and a process for its production.

A

```

10           30           50
GAATTCCCAGCTGACTCTAACCATGGAAATGGAGCTGGGTCTTTCTCTCTCTCTCTGTCAGTA
MetGluTrpSerTrpValPheLeuPheLeuSerVal

70           90           110
ACTACAGGTGTCCACTCCAGGTTTCAGCTGCAGCAGCTGACCGTGGTGGTGAACCT
ThrThrGlyValHisSerGlnValGlnLeuGlnSerAspAlaGluLeuValLysPro

130          150          170
GGGGCTTCAGTGAAGATATCCTGCAAGGCTTCTGGCTACACCTTCACTGACCATGCTATT
GlyAlaSerValLysIleSerCysLysAlaSerGlyTyrThrPheThrAspHisAlaIle

190          210          230
CACTGGCGAAGCAGAAGCCTGAACAGGCTTGGAAATGGATGGATATATTCTCCCGGA
HisTrpAlaLysGlnLysProGluGlnGlyLeuGluTrpIleGlyTyrIleSerProGly

250          270          290
AATGATGATATTAAGTACAATGAGAAGTTCGAAGGCAAGGCCACTGACTGCAGACAAA
AsnAspAspIleLysTyrAsnGluLysPheLysGlyLysAlaThrLeuThrAlaAspLys

310          330          350
TCCTCCAGCACTGCCTACATGCAGCTCAACAGCCTGACATCTGAGGATCTGCAGTGAT
SerSerSerThrAlaTyrMetGlnLeuAsnSerLeuThrSerGluAspSerAlaValTyr

370          390          410
TCTGTAAAAGATCGTACTACGGCCACTGGGGCAAGGCCACTCTCACAGTCTCTCTCA
PheCysLysArgSerTyrTyrGlyHisTrpGlyGlnGlyThrThrLeuThrValSerSer
    
```

B

```

10           30           50
ATCACACACACACACATGAGTGTGCCACTCAGGTCCTGGGGTTGCTGCTGTGGCTT
MetSerValProThrGlnValLeuGlyLeuLeuLeuTrpLeu

70           90           110
ACAGATGCCAGATGTGACATCCAGATGACTCAGTCTCCAGCCTCCCTATCTGTATCTGTG
ThrAspAlaArgCysAspIleGlnMetThrGlnSerProAlaSerLeuSerValSerVal

130          150          170
GGGAAACTGTCCACCATCACATGTCGAGCAAGTGAGAATATTACAGTAATTTAGCATGG
GlyGluThrValThrIleThrCysArgAlaSerGluAsnIleTyrSerAsnLeuAlaTrp

190          210          230
TATCAACAGAAACAGGAAAATCTCTCAGCTCCCTGGTCTATGCTGCACAACTTAGCA
TyrGlnGlnLysGlnGlyLysSerProGlnLeuLeuValTyrAlaAlaThrAsnLeuAla

250          270          290
GATGGTGTGCCATCAAGGTTTCAGTGGCAGTGGATCGGGCACAGTATTCCTCAAGATC
AspGlyValProSerArgPheSerGlySerGlySerGlyThrGlnTyrSerLeuLysIle

310          330          350
AACAGCTGCAGTCTGAAGATTTGGGAGTTACTGTCAACATTTTGGGGTACTCCG
AsnSerLeuGlnSerGluAspPheGlySerTyrTyrCysGlnHisPheTrpGlyThrPro
    
```

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon			TD	Chad

RECOMBINANT ANTIBODY AND METHOD

The present invention relates to a humanised antibody molecule (HAM) having specificity for an antigen present on certain malignant cells and to a process for its production using recombinant DNA technology.

In the present application, the term "recombinant antibody molecule" (RAM) is used to describe an antibody produced by any process involving the use of recombinant DNA technology, including any analogues of natural immunoglobulins or their fragments. The term "humanised antibody molecule" (HAM) is used to describe a molecule having an antigen binding site derived from an immunoglobulin from a non-human species, the remaining immunoglobulin-derived parts of the molecule being derived from a human immunoglobulin. The antigen binding site may comprise either complete variable domains fused onto constant domains or only the complementarity determining regions grafted onto appropriate framework regions in the variable domains. The abbreviation "MAb" is used to indicate a monoclonal antibody.

In the description, reference is made to a number of publications by number. The publications are listed in numerical order at the end of the description.

Natural immunoglobulins have been known for many years, as have the various fragments thereof, such as the Fab, (Fab')₂ and Fc fragments, which can be derived by enzymatic cleavage. Natural immunoglobulins comprise a generally Y-shaped molecule having an antigen-binding site at the end of

each upper arm. The remainder of the structure, and particularly the stem of the Y, mediates the effector functions associated with immunoglobulins.

Natural immunoglobulins have been used in assay, diagnosis and, to a more limited extent, therapy. However, such uses, especially in therapy, have been hindered by the polyclonal nature of natural immunoglobulins. A significant step towards the realisation of the potential of immunoglobulins as therapeutic agents was the discovery of monoclonal antibodies of defined specificity (1). However, most MAbs are produced by fusions of rodent spleen cells with rodent myeloma cells. They are therefore essentially rodent proteins. There are very few reports of the production of human MAbs.

Since most available MAbs are of rodent origin, they are naturally antigenic in humans. Therefore, the use of rodent MAbs as therapeutic agents in humans is inherently limited by the fact that the human subject will mount an immunological response to the MAb and will either remove it entirely or at least reduce its effectiveness.

There have therefore been made proposals for making non-human MAbs less antigenic in humans. Such techniques can be generically termed "humanizing" MAbs. These techniques generally involve the use of recombinant DNA technology to manipulate DNA sequences encoding the polypeptide chains of the antibody molecule.

Some early methods for carrying out such a procedure are described in EP-A-0 171 496 (Res. Dev. Corp. Japan), EP-A-0 173 494 (Stanford University), EP-A-0 194 276 (Celltech Limited) and WO-A-8 702 671 (Int. Gen. Eng. Inc.). The Celltech application discloses a process for preparing an

antibody molecule having the variable domains from a mouse MAb and the constant domains from a human immunoglobulin. It also shows the production of an antibody molecule comprising the variable domains of a mouse MAb, the CH1 and CL domains of a human immunoglobulin, and a non-immunoglobulin-derived protein in place of the Fc portion of the human immunoglobulin.

In an alternative approach, described in EP-A-87302620.7 (Winter), the complementarity determining regions (CDRs) of a mouse MAb have been grafted onto the framework regions of the variable domains of a human immunoglobulin using site directed mutagenesis using long oligonucleotides .

The earliest work on humanizing MAbs has been carried out based on MAbs recognising synthetic antigens, such as the NP or NIP antigens. However, examples in which a mouse MAb recognising lysozyme and a rat MAb recognising an antigen on human T cells respectively were humanized are shown by Verhoeyen et al. (2) and Reichmann et al. (3) .

It has been widely suggested that immunoglobulins, and in particular MAbs, could potentially be very useful in the diagnosis and treatment of cancer (4,5). There has therefore been much activity in trying to produce immunoglobulins or MAbs directed against tumour-specific antigens. So far, over one hundred MAbs directed against a variety of human carcinomas have been used in various aspects of tumour diagnosis or treatment (6).

There have been a number of papers published concerning the production of chimeric monoclonal antibodies recognising cell surface antigens. For instance, Sahagan et al. (7) disclose a genetically engineered murine/human chimeric antibody which

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.